PALB2、BRIP1表达与人脑胶质瘤的临床病理特征及其预后的关系  

The Relationship Between the Expression of PALB2 and BRIP1 and the Clinical Pathological Characteristics and Prognosis of Human Glioblastoma

作　　者：王晓英 万学峰 任艳霞 WANG Xiaoying;WAN Xuefeng;REN Yanxia(Zhumadian Central Hospital,Zhumadian,463000)

机构地区：[1]河南省驻马店市中心医院,463000

出　　处：《实用癌症杂志》2025年第3期401-405,共5页The Practical Journal of Cancer

基　　金：河南省高等学校重点科研项目计划(编号:16A110005)。

摘　　要：目的 探讨乳腺癌易感基因2定位协作蛋白(PALB2)、乳腺癌易感基因相互作用蛋白1(BRIP1)表达与人脑胶质瘤临床病理特征及其预后的关系。方法 选取72例人脑胶质瘤患者作为研究对象,将手术过程中取得癌组织标本纳入人脑胶质瘤组,将对应的癌旁组织标本纳入癌旁组。采用免疫组化法检测PALB2、BRIP1在人脑胶质瘤癌组织及癌旁组织中的表达情况;通过χ^(2)检验分析PALB2、BRIP1表达与人脑胶质瘤临床病理特征的关系;采用多因素Cox回归分析脑胶质瘤患者预后的影响因素。结果 人脑胶质瘤组PALB2(75.00%vs 25.00%)、BRIP1(79.71%vs 20.83%)阳性表达率高于癌旁组(P均<0.05)。病理分期为Ⅲ~Ⅳ级、肿瘤直径>5 cm、有脑水肿、低分化患者PALB2阳性表达率(88.46%vs 11.54%、93.77%vs 6.12%、86.27%vs 13.73%、93.75%vs 6.25%)、BRIP1阳性表达率(76.92%vs 23.08%、95.92%vs 4.08%、88.24%vs 11.76%、93.75%vs 6.25%)高于病理分期Ⅰ~Ⅱ级、肿瘤直径≤5 cm、无脑水肿、高分化患者(P<0.05)。肿瘤病理分级为Ⅰ~Ⅱ级(90.00%vs 42.31%)、肿瘤直径≤5 cm(91.30%vs 38.78%)、中、高分化(91.67%vs 37.50%)、无脑水肿(85.71%vs 43.14%)、PALB2阴性(88.89%vs 44.44%)、BRIP1阴性(86.67%vs 47.37%)患者3年总生存率高于病理分期Ⅲ~Ⅳ级、肿瘤直径>5 cm、有脑水肿、低分化、PALB2阳性、BRIP1阳性患者(P均<0.05)。多因素Cox回归分析显示,低分化(HR=2.625,95%CI:1.831~3.175)、PALB2阳性(HR=3.787,95%CI:2.302~5.935)、BRIP1阳性(HR=2.642,95%CI:1.112~4.761)是人脑胶质瘤患者预后的影响因素(P<0.05)。结论 PALB2、BRIP1在人脑胶质瘤中呈高表达,与肿瘤病理分期、肿瘤直径、有无脑水肿、肿瘤分化程度密切相关,可作为辅助评估患者预后的生物标记物。Objective To explore the relationship between the expression of breast cancer susceptibility gene 2 localization collaboration protein(PALB2)and breast cancer susceptibility gene interaction protein 1(BRIP1)and the clinical manifestations and prognosis of human glioma patients.Methods 72 patients with human brain glioma were selected as the subjects of this study.Cancer tissue specimens obtained during surgery were included in the human brain glioma group(n=72),and corresponding para-cancer tissue specimens were included in the para-cancer group(n=72).The expression of PALB2 and BRIP1 in tumor tissue and adjacent tissue of human brain glioma patients was detected by immunohistochemical method.The relationship between the expression of PALB2 and BRIP1 and the clinical manifestations of human brain glioma was analyzed by χ^(2) test.The prognostic factors of glioma cases were explored by multivariate Cox regression.Results The positive expression rates of PALB2(75.00%vs 25.00%)and BRIP1(79.71%vs 20.83%)in human brain glioma group were higher than those in para-cancer group(all P<0.05).The positive expression rate of PALB2(88.46%vs 11.54%、93.77%vs 6.12%、86.27%vs 13.73%、93.75%vs 6.25%)and the positive expression rate of BRIP1 in cases with tumor pathological stageⅢ~Ⅳ,tumor diameter>5 cm,brain edema and low differentiation(76.92%vs 23.08%,95.92%vs 4.08%,88.24%vs 11.76%,93.75%vs 6.25%)was higher than that of cases with gradeⅠ~Ⅱ,tumor diameter≤5 cm,no cerebral edema,and high differentiation(P<0.05).The 3-year overall survival rate of pathological grades of the tumors gradeⅠtoⅡ(90.00%vs 42.31%),tumor dia-meter≤5 cm(91.30%vs 38.78%),medium to highly differentiated(91.67%vs 37.50%),no cerebral edema(85.71%vs 43.14%),and PALB2 negative(88.89%vs 44.44%)and BRIP1 negative(86.67%vs 47.37%)was higher than those in cases with pathological stageⅢtoⅣ,tumor diameter>5cm,brain edema,low differentiation,PALB2 positive,BRIP1 positive(all P<0.05).Low differentiation(HR=2.625,95%CI:1.831~3.175),PALB2 positive(H

关 键 词：乳腺癌易感基因2定位协作蛋白 BRIP1 人脑胶质瘤 临床表现 预后 

分 类 号：R730.264[医药卫生—肿瘤]